Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Update

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 31,600 shares, a drop of 21.2% from the February 28th total of 40,100 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average daily volume of 39,500 shares, the short-interest ratio is currently 0.8 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Lisata Therapeutics in a report on Wednesday, December 11th.

Lisata Therapeutics Stock Down 2.5 %

NASDAQ:LSTA opened at $2.35 on Monday. Lisata Therapeutics has a 52 week low of $2.05 and a 52 week high of $4.20. The stock has a market cap of $20.26 million, a price-to-earnings ratio of -0.94 and a beta of 1.16. The company’s 50 day moving average price is $2.50 and its 200-day moving average price is $2.82.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.21. The business had revenue of $1.00 million for the quarter. As a group, sell-side analysts anticipate that Lisata Therapeutics will post -2.66 earnings per share for the current year.

Institutional Trading of Lisata Therapeutics

An institutional investor recently bought a new position in Lisata Therapeutics stock. Citadel Advisors LLC acquired a new stake in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,273 shares of the company’s stock, valued at approximately $69,000. Citadel Advisors LLC owned 0.28% of Lisata Therapeutics as of its most recent SEC filing. 8.94% of the stock is currently owned by institutional investors and hedge funds.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.